SMCO3

Across TCGA pan-cancer cohorts, SMCO3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMCO3 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMCO3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SMCO3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SMCO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.940	0.750	.010	30	view →
LUAD	OS	Quartile	III,IV	0.164	0.845	.006	16	view →
CCRCC	DFS	Median	All	0.974	0.876	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMCO3–PDAC (OS)

Open the PDAC breakdown →